Citigroup Reaffirms Their Hold Rating on Mayne Pharma Group Limited (MAYNF)

According to, Deakin-Bell is a 3-star analyst with an average return of 2.2% and a 66.2% success rate. Deakin-Bell covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Pro Medicus Limited, and Ramsay Health Care.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mayne Pharma Group Limited with a $0.22 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Mayne Pharma Group Limited’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment involves in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty brands segments includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment offers manufacturing and selling of branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.

Read More on MAYNF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed